Verve Capital Stock from 2010 to 2025

VERV Stock  USD 5.78  0.23  4.14%   
Verve Therapeutics Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to about 52.6 K in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals
 
Capital Stock  
First Reported
2010-12-31
Previous Quarter
89 K
Current Value
52.6 K
Quarterly Volatility
32.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 30.2 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 13.96, Dividend Yield of 0.0 or PTB Ratio of 1.01. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Verve Therapeutics Correlation against competitors.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Latest Verve Therapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Verve Therapeutics over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Verve Therapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verve Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Stock10 Years Trend
Slightly volatile
   Capital Stock   
       Timeline  

Verve Capital Stock Regression Statistics

Arithmetic Mean22,351
Geometric Mean6,090
Coefficient Of Variation144.81
Mean Deviation27,858
Median2,000
Standard Deviation32,367
Sample Variance1B
Range87K
R-Value0.79
Mean Square Error424.9M
R-Squared0.62
Significance0.0003
Slope5,359
Total Sum of Squares15.7B

Verve Capital Stock History

202552.6 K
202489 K
202382 K
202262 K
202149 K
2020 3000.0

Other Fundumenentals of Verve Therapeutics

Verve Therapeutics Capital Stock component correlations

0.990.960.65-0.87-0.890.670.990.780.991.00.981.00.880.980.940.360.92-0.43
0.990.960.62-0.9-0.860.730.990.71.00.990.980.990.880.980.920.340.89-0.4
0.960.960.49-0.92-0.950.680.950.720.960.960.960.960.840.960.980.320.9-0.65
0.650.620.49-0.52-0.480.330.580.630.620.630.560.630.570.560.550.60.630.01
-0.87-0.9-0.92-0.520.87-0.87-0.85-0.51-0.9-0.88-0.91-0.88-0.65-0.91-0.86-0.53-0.80.55
-0.89-0.86-0.95-0.480.87-0.59-0.85-0.79-0.86-0.89-0.92-0.88-0.71-0.92-0.97-0.45-0.920.77
0.670.730.680.33-0.87-0.590.670.180.730.690.730.690.350.730.540.570.46-0.27
0.990.990.950.58-0.85-0.850.670.740.990.990.970.990.890.970.920.280.87-0.41
0.780.70.720.63-0.51-0.790.180.740.70.770.750.770.690.750.820.370.84-0.45
0.991.00.960.62-0.9-0.860.730.990.70.990.980.990.880.980.920.340.89-0.4
1.00.990.960.63-0.88-0.890.690.990.770.990.981.00.870.980.930.360.91-0.43
0.980.980.960.56-0.91-0.920.730.970.750.980.980.980.811.00.930.40.93-0.48
1.00.990.960.63-0.88-0.880.690.990.770.991.00.980.870.980.930.370.9-0.42
0.880.880.840.57-0.65-0.710.350.890.690.880.870.810.870.810.84-0.050.84-0.32
0.980.980.960.56-0.91-0.920.730.970.750.980.981.00.980.810.930.40.93-0.48
0.940.920.980.55-0.86-0.970.540.920.820.920.930.930.930.840.930.340.94-0.69
0.360.340.320.6-0.53-0.450.570.280.370.340.360.40.37-0.050.40.340.32-0.22
0.920.890.90.63-0.8-0.920.460.870.840.890.910.930.90.840.930.940.32-0.52
-0.43-0.4-0.650.010.550.77-0.27-0.41-0.45-0.4-0.43-0.48-0.42-0.32-0.48-0.69-0.22-0.52
Click cells to compare fundamentals

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Stock89 K52.6 K
Issuance Of Capital Stock46.7 M44.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.